Ignite Creation Date:
2025-12-24 @ 6:34 PM
Ignite Modification Date:
2026-01-10 @ 10:47 AM
Study NCT ID:
NCT04239157
Status:
RECRUITING
Last Update Posted:
2025-11-18
First Post:
2019-12-31
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-08-25
Start Date Type:
ACTUAL
Primary Completion Date:
2026-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2019-12-31
First Submit QC Date:
None
Study First Post Date:
2020-01-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-17
Last Update Post Date:
2025-11-18
Last Update Post Date Type:
ESTIMATED